Amol Akhade Highlights Tarlatamab’s OS Benefit in SCLC
Dr. Amol Akhade, a Senior Medical & Hemato-Oncologist based in Mumbai, India, shared insights about Tarlatamab on LinkedIn
“Big win in SCLC. Amgen’s IMDELLTRA (tarlatamab), a DLL3-targeting BiTE, shows OS superiority over chemo in 2L SCLC (DeLLphi-304). First-in-class, tumor-selective T-cell engager. This could reshape the 2L standard of care. Do check out Median PFS and OS for existing second-line options in SCLC. How much better will it be? My guess is median PFS 4.5 months and OS 14.3 months. What do you think? Let’s wait for further data “
This post by Dr. Amol Akhade highlights a significant development in small cell lung cancer (SCLC) treatment. Tarlatamab (IMDELLTRA), a first-in-class DLL3-targeting bispecific T-cell engager (BiTE) from Amgen, has demonstrated overall survival (OS) superiority over chemotherapy in the second-line (2L) setting in the ongoing DeLLphi-304 trial. If further data confirms these early results, this could redefine the treatment landscape for SCLC, a disease notorious for its aggressive nature and limited therapeutic options.
Akhade raises a thought-provoking point by estimating potential median outcomes—progression-free survival (PFS) of 4.5 months and OS of 14.3 months, figures that, if validated, would represent a major leap forward compared to existing second-line therapies. With DLL3 now being successfully targeted in a clinical setting, this may usher in a new era of precision immunotherapy in lung cancer.
You Can Read More on Tarlatamab on OncoDaily
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023